A Phase 1, Open-Label, Randomized, Single Dose, 3-Way Crossover Study to Address the Relative Bioavailability of Solifenacin Liquid Suspension 10mg (Fed and Fasting) Versus the VESIcare (Solifenacin Succinate) 10 mg Tablet (Fasting) in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2009
At a glance
- Drugs Solifenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 11 Dec 2009 Status changed from active, no longer recruiting to completed.
- 21 Nov 2009 New trial record